Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
| CAN-FITE BIOPHARMA LTD. (NYSE: CANF) | Delayed: 2.14 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.14 | 52 Week High | $3.89 | |||
| Open | $2.14 | 52 Week Low | $1.85 | |||
| Day High | $2.14 | P/E | N/A | |||
| Day Low | $2.11 | EPS | $0.00 | |||
| Volume | 24,400 | |||||
| CAN-FITE BIOPHARMA LTD. (NYSE: CANF) | Delayed: 2.14 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.14 | 52 Week High | $3.89 | |||
| Open | $2.14 | 52 Week Low | $1.85 | |||
| Day High | $2.14 | P/E | N/A | |||
| Day Low | $2.11 | EPS | $0.00 | |||
| Volume | 24,400 | |||||
